Axelopran
Clinical data
ATC code
  • none
Identifiers
  • 3-[(1R,5S)-8-[2-[cyclohexylmethyl-[(2S)-2,3-dihydroxypropanoyl]amino]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC26H39N3O4
Molar mass457.615 g·mol−1
3D model (JSmol)
  • C1CCC(CC1)CN(CCN2C3CCC2CC(C3)C4=CC=CC(=C4)C(=O)N)C(=O)C(CO)O
  • InChI=1S/C26H39N3O4/c27-25(32)20-8-4-7-19(13-20)21-14-22-9-10-23(15-21)29(22)12-11-28(26(33)24(31)17-30)16-18-5-2-1-3-6-18/h4,7-8,13,18,21-24,30-31H,1-3,5-6,9-12,14-17H2,(H2,27,32)/t21-,22+,23-,24-/m0/s1
  • Key:ATLYLVPZNWDJBW-KIHHCIJBSA-N

Axelopran (INN, USAN) (developmental code name TD-1211) is a drug which is under development by Theravance Biopharma and licensed to Glycyx for all indications. It acts as a peripherally acting μ-opioid receptor antagonist and also acts on κ-, and δ-opioid receptors, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Recent data suggests that μ-opioid antagonists have a direct effect on overall survival in patients with advanced cancer.[1]

A μ-opioid agonist (e.g., morphine) have been shown to have multiple pro-tumor effects in vivo and in vitro, which can be blocked with μ-opioid antagonists including promoting angiogenesis,[2][3] accelerating tumor cell proliferation,[4][5] and modifying the response to chemotherapeutics. An extensive body of literature has shown diverse and profound immunosuppressive effects of μ-opioid activation in vivo and in vitro.[6]

Recent data for axelopran in three different pre-clinical models of cancer shows that a μ-opioid antagonist isolates distinct effects of the endogenous opioid system on tumor growth and works in combination with checkpoint inhibitors. The study of axelopran in melanoma in a zebrafish embryo model with an immature immune system and no microbiome tested axelopran direct effects on tumor growth and metastasis. The study of breast cancer in chicken eggs with a functional immune system and no microbiome tested the direct effect of axelopran on tumor weight, tumor immune infiltration, metastasis and angiogenesis. The study of axelopran in MC-38 syngeneic colorectal cancer in mice in combination with murine anti-PD-1 antibody tested the effect of a μ-opioid blockade on tumor volume and survival in a full in vivo model with both fully functional immune system and mature gut function and enteric microbiome.

All three pre-clinical studies showed a significant impact of axelopran on their respective endpoints, suggesting that μ-opioid blockade is useful across different tumor types and has multiple mechanisms of action, including direct suppression of tumor cell proliferation, angiogenesis and metastasis, and immune surveillance. Furthermore, axelopran and murine anti-PD-1 antibody were synergistic in slowing tumor growth and increasing survival in the syngeneic mouse model.

Axelopran has potent μ-opioid receptor antagonist activity on the gastrointestinal tract in vivo, and thus it produces a dose-dependent inhibition of opioid-induced delaying in gastric emptying in mice and rats following subcutaneous or oral administration.[7][8]

See also

References

  1. ^ Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J (September 2016). "Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer". Annals of Oncology. 27 (11): 2032–2038. doi:10.1093/annonc/mdw317. PMC 6267944. PMID 27573565.
  2. ^ Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP (August 2002). "Morphine Stimulates Angiogenesis by Activating Proangiogenic and Survival-promoting Signaling and Promotes Breast Tumor Growth". Cancer Research. 62 (15): 4491–4498. PMID 12154060.
  3. ^ Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J (September 2006). "Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation". Microvascular Research. 72 (1–2): 3–11. doi:10.1016/j.mvr.2006.04.004. PMID 16820176.
  4. ^ Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, et al. (October 2014). "Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer". Anesthesia and Analgesia. 113 (6): 1353–1364. doi:10.1213/ANE.0b013e318232b35a. PMC 3725599. PMID 22003224.
  5. ^ Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA (March 2014). "The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer". PLOS ONE. 9 (3): e91577. Bibcode:2014PLoSO...991577L. doi:10.1371/journal.pone.0091577. PMC 3963855. PMID 24662916.
  6. ^ Eisenstein TK (2019). "The Role of Opioid Receptors in Immune System Function". Frontiers in Immunology. 10: 2904. doi:10.3389/fimmu.2019.02904. PMC 6934131. PMID 31921165.
  7. ^ Armstrong SR, Campbell CB, Richardson CL, Vickery RG, Tsuruda PR, Long DD, et al. (June 2013). "The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity". Naunyn-Schmiedeberg's Archives of Pharmacology. 386 (6): 471–8. doi:10.1007/s00210-013-0844-5. PMID 23512167. S2CID 15482326.
  8. ^ Tsuruda PR, Vickery RG, Long DD, Armstrong SR, Beattie DT (June 2013). "The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist". Naunyn-Schmiedeberg's Archives of Pharmacology. 386 (6): 479–91. doi:10.1007/s00210-013-0850-7. PMID 23549670. S2CID 18963203.


Categories